Ranking Year:
# | Company Name | Region | Tech Topics | Total |
|---|
1 | Patent: 4 | |||
2 | Patent: 4 | |||
3 | Patent: 2 | |||
4 | Patent: 2 | |||
5 |  | Patent: 1 |
Top 5 Fast-growings companies in Ribociclib
by Most Patent Filing In 5 Years in the United States in 2022
The Ribociclib top 5 is Discovery PatSnap’ annual ranking of the top 5 Most Patent Filing In 5 Years Ribociclib Fast-growings in the United States. Discovery has identified the top key players, startups & unicorns, fast-growings, news entrants in 2022, ranking from differnt perspectives, including patent filing intensity, academic research capability, news media heat. The company list is generated from various data types.
Ribociclib (trade name Kisqali) is an inhibitor of cyclin D1/CDK4 and CDK6, and is used for the treatment of certain kinds of breast cancer. It is also being studied as a treatment for other drug-resistant cancers. It was developed by Novartis and Astex Pharmaceuticals.
Ranking:
Page generation time:
Jul 07 2025